Chongqing Huiyuan Pharma Acquires Singapore Chinese Medicines And Health
This article was originally published in PharmAsia News
Executive Summary
Chongqing Huiyuan Pharma has recently completed the acquisition of Singapore's second-largest pharmaceutical retail chain company - Singapore Chinese Medicines and Health - with RMB 10 million ($1.46 million). Huiyuan will set up a large-scale one-stop TCM supermarket in Singapore that integrates diagnosis services by TCM physicians and sale of health products and Chinese herbal slices. The firm will also establish branches in Southeast Asia to develop TCM clinics, training, exhibition and wholesale businesses. The acquisition is set to boost sales of Chongqing-made Chinese crude medicines and herbal slices in the Singapore market, as well as enhance Chongqing city's TCM product expansion in Southeast Asia. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.